Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 13/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653716 | 0.87 | DRD2 (0.50) | DRD2DRD4DRD3CTSSOPRM1 | |
| SCHEMBL6649677 | 0.83 | CTSS (0.47) | DRD2DRD4DRD3CTSSOPRM1 | |
| SCHEMBL6654442 | 0.82 | CTSS (0.49) | DRD2DRD4DRD3CTSSOPRM1 | |
| SCHEMBL6653777 | 0.80 | CTSS (0.57) | CTSS | |
| SCHEMBL6658783 | 0.80 | CHRM2 (0.51) | DRD2DRD4DRD3CTSSOPRM1 | |
| SCHEMBL17814060 | 0.80 | CTSS (0.58) | CTSSOPRM1SIGMAR1CHRM2CHRM3 | |
| SCHEMBL6651962 | 0.77 | CTSS (0.56) | CTSS | |
| SCHEMBL6652063 | 0.76 | DRD2 (0.48) | DRD2DRD4DRD3CTSSOPRM1 | |
| SCHEMBL6653626 | 0.75 | CTSS (0.57) | CTSS | |
| SCHEMBL6651283 | 0.75 | OPRM1 (0.41) | CTSSOPRM1SIGMAR1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | claimed |
| US-20030069276-A1 | Amino piperidine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | US | claimed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | claimed |
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069276-A1 | Amino piperidine derivatives | CCR5, CCR2, CXCR4 | DRD2 346/4885DRD4 429/4885DRD3 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.